E-Proteins SRL
1.0 FTEThe score of E-Proteins shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +39 % Total assets +48 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →E-Proteins's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jun 2026
- Year ended 31 Dec 2024filed on 26 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 23 Aug 2022
E-Proteins's financial analysis
- Solvency84.6%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of E-Proteins
E-Proteins's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0843.454.986
- VAT number
- BE0843454986
- Peppol
- Registered · 0208:0843454986 · as of 23 Oct 2026
- Legal form
- SRL
- Incorporated
- 07 Feb 2012
- Registered office
- 5030 Gembloux
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 09 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
E-Proteins (SRL) has been based in Gembloux since 2012, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 233,193 € and equity of €1.45m; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 84.6%, above the median of its sector (57.9%).
Companies similar to E-Proteins
Companies in the same business, of comparable size and area, outside its group.
- Matthys Charlotte Research and experimental development on natural sciences and engineering Aalter · balance sheet €1.65m
- Novalix Belgium Research and experimental development on natural sciences and engineering Braine-l'Alleud · balance sheet €1.64m
- Otorino Research and experimental development on natural sciences and engineering Waterloo · balance sheet €1.86m
- Trim Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.50m
- ReWind Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €2.09m
- Apotheker-Bioloog Dimitri Baetens Research and experimental development on natural sciences and engineering Lokeren · balance sheet €2.15m
- Sunrock Assets Belgium I Research and experimental development on natural sciences and engineering Brussels · balance sheet €2.21m
- Eilc Solar 21 Research and experimental development on natural sciences and engineering Herentals · balance sheet €1.32m
Frequently asked questions about E-Proteins
What is the revenue of E-Proteins?
E-Proteins files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of E-Proteins?
In Belgium, the VAT number is the company number prefixed with BE: BE0843454986 for E-Proteins, if the company is VAT-registered. Its company number (CBE) is 0843.454.986.
Where is the registered office of E-Proteins?
According to the CBE register, the registered office of E-Proteins is in 5030 Gembloux.
What is the equity of E-Proteins?
At the close of the 2025 financial year, the equity of E-Proteins amounts to 1,449,395 €, a solvency of 84.6% of total assets.
How many people work at E-Proteins?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages E-Proteins?
The register lists 3 active mandates at E-Proteins. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of E-Proteins
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →